Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 9/20 | 1.00 |
| ▸ | ATIC | P31939 | 4/20 | 0.71 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.60 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.58 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lometrexol SCHEMBL10067961 | 1.00 | GART (1.00) | GARTATICSOSTMTHFD2MTHFD1 | |
| Lometrexol SCHEMBL14469100 | 1.00 | GART (1.00) | GARTATICSOSTMTHFD2MTHFD1 | |
| Lometrexol SCHEMBL17520098 | 1.00 | GART (1.00) | GARTATICSOSTMTHFD2MTHFD1 | |
| Lometrexol SCHEMBL18530 | 0.88 | GART (0.78) | GARTATIC | |
| SCHEMBL10512730 | 0.87 | GART (0.78) | GARTATICSOSTMTHFD1 | |
| SCHEMBL10512772 | 0.87 | GART (0.78) | GARTATICSOSTMTHFD1 | |
| Lometrexol SCHEMBL29356838 | 0.87 | GART (0.77) | GARTATICSOST | |
| SCHEMBL9837105 | 0.87 | GART (0.77) | GARTATICSOSTMTHFD2MTHFD1 | |
| Lometrexol SCHEMBL21248426 | 0.87 | GART (0.77) | GARTATIC | |
| SCHEMBL9536119 | 0.87 | GART (0.77) | GARTATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390297-A1 | USE OF NUCLEOTIDE SYNTHESIS INHIBITORS FOR TARGETED THERAPY IN MLL3/4 COMPASS MUTANT CANCER | NORTHWESTERN UNIVERSITY | 2023-12-07 | — | — | US | disclosed |
| WO-2017031176-A1 | MONOCYCLIC, THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF THE SAME | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-02-23 | — | — | WO | disclosed |
| US-8530653-B2 | Enzyme inhibiting compounds | CHELSEA THERAPEUTICS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530653-B2 | Enzyme inhibiting compounds | CHELSEA THERAPEUTICS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110112126-A1 | ENZYME INHIBITING COMPOUNDS | CHELSEA THERAPEUTICS, INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112126-A1 | ENZYME INHIBITING COMPOUNDS | CHELSEA THERAPEUTICS, INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011056957-A2 | ENZYME INHIBITING COMPOUNDS | CHELSEA THERAPEUTICS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110081338-A1 | METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION | CHELSEA THERAPEUTICS, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110082149-A1 | METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION | CHELSEA THERAPEUTICS, INC. | 2011-04-07 | — | — | US | disclosed |
| US-7829708-B2 | Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation | CHELSEA THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829708-B2 | Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation | CHELSEA THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081338-A1 | METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION | DHFR, MTHFD1, MTHFD2 | GART 403/4885ATIC 421/4885SOST 2483/4885 |
| US-20110082149-A1 | METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION | DHFR, MTHFD1, MTHFD2 | GART 403/4885ATIC 421/4885SOST 2483/4885 |
| US-20110112126-A1 | ENZYME INHIBITING COMPOUNDS | FPGS, DHFR, TYMS | GART 19/4885ATIC 150/4885SOST 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.